Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Operating Income (2016 - 2025)

Tvardi Therapeutics' Operating Income history spans 13 years, with the latest figure at -$7.6 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 29.76% to -$7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.8 million, a 53.53% increase, with the full-year FY2025 number at -$26.7 million, up 4.84% from a year prior.
  • Operating Income hit -$7.6 million in Q4 2025 for Tvardi Therapeutics, down from -$5.9 million in the prior quarter.
  • Over the last five years, Operating Income for TVRD hit a ceiling of -$1.1 million in Q3 2021 and a floor of -$33.5 million in Q4 2021.
  • Historically, Operating Income has averaged -$18.8 million across 5 years, with a median of -$23.7 million in 2021.
  • Biggest five-year swings in Operating Income: surged 93.4% in 2021 and later plummeted 2021.44% in 2022.
  • Tracing TVRD's Operating Income over 5 years: stood at -$33.5 million in 2021, then grew by 6.61% to -$31.3 million in 2022, then dropped by 4.15% to -$32.6 million in 2023, then soared by 66.87% to -$10.8 million in 2024, then increased by 29.76% to -$7.6 million in 2025.
  • Business Quant data shows Operating Income for TVRD at -$7.6 million in Q4 2025, -$5.9 million in Q3 2025, and -$8.9 million in Q2 2025.